Oral sildenafil therapy improves health-related quality of life and functional status in pulmonary arterial hypertension

详细信息    查看全文

• 作者：Raymond Ching-Chiew Wong ; Geok Mui Koh ; Poh Hoon Choong ; Wei Luen James Yip
• 关键词：Pulmonary arterial hypertension ; Oral sildenafil ; Health-related quality of life ; Functional class
• 刊名：International Journal of Cardiology
• 出版年：2007
• 出版时间：31 July 2007
• 年：2007
• 卷：119
• 期：3
• 页码：400-402
• 全文大小：160 K

文摘

Sildenafil, a selective inhibitor of cyclic guanosine monophosphate (cGMP) specific phosphodiesterase-5 inhibitor, has shown promising results as a novel oral monotherapy in the treatment of pulmonary arterial hypertension (PAH). We conducted a cross-sectional survey of 19 consecutive PAH patients, aged 16–75 years, with WHO functional class II or worse over 3 months of oral sildenafil. Improvement in exercise capacity was achieved in 15/19 (79 % ) patients. 6-minute walk test distance increased from 299 ± 118 m to 360 ± 127 m, p = 0.016, and WHO functional class decreased significantly. Both PASP and CI showed a non-significant trend toward improvement. Patients also reported significant improvement in physical (p = 0.002) and social (p < 0.001) functioning, and general health (p = 0.01) of Rand SF-36 questionnaire. There was improvement in domains of role limitation due to physical health (p = 0.16), emotion (p = 0.14), and energy level (p = 0.4). Our study suggests that oral sildenafil monotherapy is effective in improving exercise capacity and health-related quality of life amongst PAH patients.